key: cord-0784543-oixskii9
authors: Volack, Trey; Dallaire, Stephanie; Chin, Ephrem; Hedge, Madhuri; Pinget, Siris; Wright, Jeneau; Cramer, Amanda
title: eP411: Tackling the COVID-19 pandemic by utilizing next generation sequencing technologies
date: 2022-03-31
journal: Genetics in Medicine
DOI: 10.1016/j.gim.2022.01.446
sha: 04cf7025fa5f5a98e841c81f15a543d89bca0ea1
doc_id: 784543
cord_uid: oixskii9

nan

Tackling the COVID-19 pandemic by utilizing next generation sequencing technologies Trey Volack 1 , Stephanie Dallaire 1 , Ephrem Chin 1 , Madhuri Hedge 1 , Siris Pinget 1 , Jeneau Wright 1 , Amanda Cramer 1 1 PerkinElmer Introduction: The COVID-19 outbreak caused by SARS-CoV-2 has led to major socio-economic disruption worldwide and the pandemic has yet to secede after more than 18 months. As of November 2021, SARS-CoV-2 has infected over 251 million people and caused over 5 million deaths worldwide. The discovery of aggressive variants of the virus has shown that monitoring for variants associated with changes to infection outcome and transmission of SARS-CoV-2 is critical to ensure the success of vaccination programs and establish robust public health responses. A sample identified positive for COVID-19 using an RT-PCR assay, then that sample can be tested to determine if it has a SARS-CoV-2 Variant of Concern (VOC). Next Generation Sequencing (NGS) is ideal for this as its high resolution enables scientists to identify all variants, known and unknown, providing insights to SARS-CoV-2 viral evolution. Methods: Our laboratory is one of the largest COVID testing laboratories set up at apex largest outbreak of SARS-CoV-2 patients California state had seen since the beginning of the pandemic. The laboratory was set up in a total of 8 weeks which included reagent supply, staff, and operate a high-throughput, large scale SARS-CoV-2 testing facility which is capable of processing 150 thousand samples per day. To date, our laboratory has tested over 6 million patient samples for COVID-19 since its inception in November 2020 with a total positivity rate of 8.07% at this reporting. Due to the labs' ability to process SARS-CoV-2 patient samples at such a high-throughput with a turnaround time averaging 12.2 hours per sample, we quickly utilized our ability to rapidly mobilize the lab's skilled scientists to efficiently implement NGS at the lab. We exercised the collaborative efforts of the lab team along with experts from multiple other divisions including R&D, Genomics, and Business to build, test, and release, for research use only, a proprietary NGS sequencing kit that utilizes robust NGS reagents in conjunction with a community designed Artic Primer set. Discussion in the lab about implementing NGS took place in February 2021 and by March 2021, we were fully operational and had begun to sequence these positive samples for epidemiological purposes. A streamlined process was established within four weeks using robotic automation as well as training an inexperienced staff running 4 shifts for a 24/7 lab operation. The laboratory utilizes two Illumina platforms, the NovaSeq and MiSeq systems to process high sample throughput and high priority samples. The use of our proprietary NGS kit allows for 1536 unique barcodes so that a high throughput of samples can be run on one flowcell, and this kit design allowed for our lab to utilize a full Illumina S4 flowcell with approximately 6144 samples at a time. Results: At this reporting, more than 115,000 samples have been sequenced using the NGS kit to determine the populations of VOCs rampant in California. This is broken up into two workflows: routine high throughput processing on the NovaSeq with a turnaround time of 7 days and STAT sample manual processing on the MiSeq with a turnaround time of 48 hours. The lab can process up to 24 STAT samples daily and an average of 5000 routine patient samples per week. SARS-CoV-2 in patient samples is measured by qPCR; where having a cycle threshold (Ct) cutoff value determines the presence and amount of virus detected in a sample. Of these samples approximately 35% (~39,200) have been weakly detected with a Ct value greater than 33. Samples with high Ct values, which are indicative of lower viral titer traditionally do not meet the requirements for sequencing set forth in other laboratories. Lower viral titer leads to lower nucleic acid concentration which causes under clustering leading to total flowcell failure and more importantly, missed patient results. Conclusion: Due to our high throughput automated NGS workflow plus the robust NGS reagents in conjunction with a community designed Artic Primer set, our laboratory was able to successfully sequence 40% of these high Ct value sample which would have been rejected elsewhere. Due to our laboratory's unique sequencing methods, the government is able to closely monitor and track emerging VOCs within the state. We have traced the increase of pathogenic variants such as Delta as it first appeared in California, to now circulating in the population at 85% of all VOCs detected. This epidemiological information is a crucial tool in fighting the COVID-19 pandemic, providing relevant data to authorities and researchers to understand SARS-CoV-2 infection and transmission. https://doi.org/10. 1016/j.gim.2022.01.446 eP412 An evidence-based framework to evaluate Melanocortin-4 Receptor (MC4R) pathway relevance for obesity-associated genes Megan Vogel 1 , Ida Moeller 1 , Alastair Garfield 1 , Bhavik Shah 1 1 Rhythm Pharmaceuticals, Boston, MA Introduction: The MC4R pathway is the principal regulator of mammalian energy balance through its modulation of energy intake and energy expenditure. Variants in genes associated with the MC4R pathway can result in rare genetic diseases of obesity. Clinical data in patients with certain genetic defects in the MC4R pathway indicate that setmelanotide, an MC4R agonist, may effectively reduce weight and hunger in scientifically rationalized obese subpopulations in which MC4R-pathway deficit is a contributing factor to obesity. Here we introduce an evidence-based framework designed to evaluate various genes' relevance to the MC4R pathway to identify those genetic patient populations most likely to benefit from long-term setmelanotide therapy. Methods: This framework utilizes a set of clinical (human genetics) and non-clinical experimental evidence to evaluate MC4R pathway relevance and is based on the core principles of the NIH ClinGen Gene-disease Clinical Validation approach which is the industry standard for assessing gene-disease relationships. Human genetic evidence helps define the contribution of the gene to human obesity, while experimental evidence assesses involvement of the gene in the function of MC4R pathway. The cumulative weight of this evidence is used to classify MC4R pathway genes into 4 strength-based tiers: very strong, strong, moderate, weak. The nature, quantity, and quality of evidence required for each tier builds upon that of the previous tier, with higher ranked genes being more likely to define patient populations potentially responsive to long-term setmelanotide treatment. Results: Based on a comprehensive literature review, 118 MC4R pathway genes were identified and rank ordered: 8 "very strong", 29 "strong", 22 "moderate", 59 "weak". Importantly, clinically meaningful weight and hunger score reductions following treatment with setmelanotide have been previously demonstrated in patients with obesity due to variants in 6 genes, all initially classified as "very strong" or "strong", lending credence to this framework for the selection of patient populations most likely to benefit from long-term setmelanotide therapy. Conclusion: This framework provides robust means of selecting MC4R pathway relevant genes and supports clinical investigation of setmelanotide responsiveness in an additional 31 "very strong/strong" genes including LEP, SIM1, MRAP2, and KSR2. A clinical trial in patients with these 31 gene variants will commence before the end of 2021.

https://doi.org/10.1016/j.gim.2022.01.447 eP413 Type II cat eye syndrome in a newborn with intrauterine growth retardation and echogenic intracardiac focus during pregnancy Jiyong Wang 1 , Marsha Waters 1 , Loretta Witt 1 , Sarah Miller 1 , Mary Alice Moore 1 , Camerun Washington 1 , Curtis Rogers 1 , Kameryn Butler 1 , Benjamin Hilton 1 , Barbara DuPont 1 1 Greenwood Genetic Center

the most frequently identified chromosomal disorder caused by deletion of the region (recurrent breakpoints BP-A to -D), and cat eye syndrome (CES), which is usually caused by the presence of a bisatellited supernumerary marker chromosome (SMC) resulting in tetrasomy of 22q11.1q11.21. CES is characterized clinically by variable features that may include: coloboma of the iris, anal atresia with fistula, preauricular tags and/or pits, downslanting palpebral fissures, congenital heart defects, renal malformations, and normal or near-normal intellectual development. Based on the locations of the involving breakpoints, CES was divided into two types: type I CES chromosomes are within the interval of BP-A, whereas at least one of the breakpoints in type II CES chromosomes involves in the distal breakpoint in the DGS/VCFS region (BP-D). However, individuals with the clinical diagnosis of type II CES are rarer, compared to type I CES. Case presentation: Here we reported a newborn with intrauterine growth retardation and echogenic intracardiac focus during pregnancy. The routine chromosome analysis identified the presence of a bisatellited dicentric SMC of chromosome 22q11.21. Chromosomal microarray found a triplication of the 22q11.1q11.21 region and a duplication of the 22q11.21 region. The fluorescence in situ hybridization (FISH) analysis with a probe specific to the 22q11.2/ DGS/VCFS region was consistent with both of these analyses